Relmada outlines Phase 3 trial plans for bladder cancer drug NDV-01
Go back to Relmada outlines Phase 3 trial plans for bladder cancer drug NDV-01| (NASDAQ: RLMD) | Delayed: 4.56 +0.49 (12.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.07 | 52 Week High | $4.10 | |||
| Open | $4.60 | 52 Week Low | $0.87 | |||
| Day High | $4.65 | P/E | N/A | |||
| Day Low | $4.30 | EPS | $0.00 | |||
| Volume | 2,065,920 | |||||
